758-17-8

Usage

Safety Profile

Suspected carcinogen with experimental carcinogenic data. Poison by ingestion route. Mutation data reported. When heated to decomposition it emits toxic fumes of NOx. See also HYDRAZINE.

InChI:InChI=1/C2H6N2O/c1-4(3)2-5/h2H,3H2,1H3

Upstream product

• 64-18-6 formic acid 
• 60-34-4 methylhydrazine 
• 107-31-3 Methyl formate 
• 16694-46-5 ethyl formimidate hydrochloride 
• 109-94-4 formic acid ethyl ester 
• 302-15-8 methylhydrazine sulfuric acid 

Downstream Products

• 61748-15-0 Formic acid N'-dec-(Z)-ylidene-N-methyl-hydrazide 
• 61748-13-8 Formic acid N-methyl-N'-oct-(Z)-ylidene-hydrazide 
• 34771-32-9 2-Cyclohexyliden-1-formyl-1-methylhydrazin 
• 61748-16-1 Formic acid N-methyl-N'-[1-phenyl-meth-(Z)-ylidene]-hydrazide 
• 62080-57-3 Formic acid N'-but-(Z)-ylidene-N-methyl-hydrazide 
• 57590-22-4 Hexanal-N-methyl-N-formyl-hydrazon 
• 57590-21-3 3-Methylbutanal-N-methyl-N-formyl-hydrazon 
• 100276-64-0 2-(2,3,4,5-Tetrafluorbenzoyl)-3-(2-formyl-2-methylhydrazino)acrylsaeure-ethylester 
• 109308-98-7 2-(2,4-Dichlor-benzoyl)-3-(2-formyl-2-methylhydrazino)acrylsaeure-ethylester 
• 109308-77-2 2-(2,4-Dichlor-5-nitro-benzoyl)-3-(2-formyl-2-methylhydrazino)acrylsaeure-ethylester 
• 102618-08-6 2-(2,4-Dichlor-5-fluor-benzoyl)-3-(2-formyl-2-methylhydrazino)acrylsaeure-ethylester 
• 109308-99-8 2-(2,4-Dichlor-5-fluor-3-nitrobenzoyl)-3-(2-formyl-2-methylhydrazino)acrylsaeure-ethylester 
• 109309-00-4 2-(2,4,5-Trichlor-3-nitrobenzoyl)-3-(2-formyl-2-methylhydrazino)acrylsaeure-ethylester 
• 109308-97-6 ethyl 3-N-formyl-N-methylhydrazyl-2-(2,4-dichloro-5-fluoro)benzoylacrylate 

Relevant academic research and scientific papers

HETEROCYCLIC COMPOUNDS FOR INHIBITING TYK2 ACTIVITIES

Provided are Compounds 1-8, and their pharmaceutically acceptable salts or prodrugs thereof. Compounds 1-8 are selective binders to TYK2's JH2 and they exhibit significant inhibitory effects on the physiological function of TYK2 and they have excellent in vivo pharmacokinetic properties. Compounds 1-5 and 7 have several deuterium substitutions on methyl to improve pharmacokinetic (PK) properties.

CRYSTALLINE FORM OF 6-(CYCLOPROPANECARBOXAMIDO)-4-((2-METHOXY-3-(1-METHYL-1H-1,2,4-TRIAZOL-3-YL)PHENYL)AMINO)-N-(METHYL-D3) PYRIDAZINE-3-CARBOXAMIDE

Disclosed is crystalline Form B of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl) amino)-N-(methyl-d3)pyridazine-3-carboxamide. Form B is the HCl salt of a neat crystalline form. Characterization data for Form B are disclosed.

PROCESS FOR THE PREPARATION OF 6-(CYCLOPROPANEAMIDO)-4-((2-METHOXY-3-(1-METHYL-1H-1,2,4-TRIAZOL-3-YL)PHENYL)AMINO)-N-(METHYL-D3)PYRIDAZINE-3-CARBOXAMIDE

The invention relates to an improved process for synthesizing 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide of the formula: [INSERT CHEMICAL STRUCTURE HERE] Compound I is currently in clinical trials for the treatment of auto-immune and auto-inflammatory diseases such as psoriasis.

Synthesis and characterization of two formyl 2-tetrazenes

The synthesis of two formyl 2-tetrazenes, namely, (E)-1-formyl-1,4,4- trimethyl-2-tetrazene (2) and (E)-1,4-diformyl-1,4-dimethyl-2-tetrazene (3), by oxidation of (E)-1,1,4,4-tetramethyl-2-tetrazene (1) using potassium permanganate in acetone solution is presented. Compound 3 was also synthesized in an improved yield from the oxidation of 1-formyl-1-methylhydrazine (4 a) using potassium permanganate in acetone. Both compounds 2 and 3 were characterized by analytical (elemental analysis, GC-MS) and spectroscopic methods (1H, 13C, and 15N NMR spectroscopy, and IR and Raman spectroscopy). In addition, the solid-state structures of the compounds were confirmed by low-temperature X-ray analysis. (Compound 2: triclinic; space group P-1; a=5.997(1) A, b=8.714(1) A, c=13.830(2) A; α=107.35(1)°, β=90.53(1)°, γ=103.33(1)°; VUC=668.9(2) A3; Z=4; ρcalc=1.292 cm-3. Compound 3: monoclinic; space group P21/c; a=5.840(2) A, b=7.414(3) A, c=8.061(2) A; β=100.75(3) °; VUC=342(2) A3; Z=2; ρcalc=1. 396 g cm-3.) The vibrational frequencies of compounds 2 and 3 were calculated using the B3LYP method with a 6-311+G(d,p) basis set. We also computed the natural bond orbital (NBO) charges using the rMP2/aug-cc-pVDZ method and the heats of formation were determined on the basis of their electronic energies. Furthermore, the thermal stabilities of these compounds, as well as their sensitivity towards classical stimuli, were also assessed by differential scanning calorimetry and standard BAM tests, respectively. Lastly, the attempted synthesis of (E)-1,2,3,4-tetraformyl-2-tetrazene (6) is also discussed.

A one-pot process for the regioselective synthesis of 1,3,4-trisubstituted-1H-pyrazoles

This Letter reports a facile and regioselective one-pot synthesis of 1,3,4-trisubstituted-1H-pyrazoles. It comprises a three-step telescoped sequence, which has been utilised in the production of a variety of differentially substituted pyrazoles.

Process for the manufacture of a tricyclic compound

A process for preparing a compound of formula (I) or a phamaceutically-acceptable salt thereof, comprising: 1) reacting a compound. of formula (III), in which R is a straight or branched chain alkyl having from one to four carbon atoms, with an alkali metal hydroxide in an aqueous medium at a temperature of about 80° to 120° C. and time of about 20 to 100 hours to form a reaction product; 2) cyclizing the reaction product of step 1) with formic acid and formaldehyde to form a formiate compound; and 3) neutralizing the formiate compound of step 2) with an aqueous base.